含或不含硼替佐米的联合化疗治疗伴肾功能不全的初诊多发性骨髓瘤患者的疗效分析
被引量：5
摘要
肾功能不全是多发性骨髓瘤（MM）的常见并发症之一，20％～40％的新诊断患者存在不同程度的肾功能不全，其中部分患者在诊断时已经发生尿毒症，预后不良。随着蛋白酶体抑制剂硼替佐米的临床应用，MM患者的疗效得到明显改善。我们对含或不含硼替佐米的联合化疗方案治疗伴肾功能不全的初诊MM患者临床疗效进行了分析比较。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2010年第6期423-425,共3页
Chinese Journal of Hematology
基金
国家自然科学基金（30872982）
北京市自然科学基金（7082036）
参考文献13
-
1Eleutherakis-Papaiakovou V,Bamias A,Gika D,et al.Renal failare in multiple myeloma:incidence,correlations,and prognostic significance.Leuk Lymphoma,2007,48:337-341.
-
2Kyle RA,Rajkumar SV.Criteria for diagnosis,staging,risk stratification and response assessment of multiple myeloma.Leukemia,2009,23:3-9.
-
3Durie BG,Harousseau JL,Miguel JS,et al.International uniform response criteria for multiple myeloma.Leukemia,2006,20:1467-1473.
-
4Kellum JA,Hoste EA.Acute kidney injury:epidemiology and assessment.Scand J Clin Lab Invest Suppl,2008,241:6-11.
-
5Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment.Semin Radiat Oncol,2003,13:176-181.
-
6Greipp PR,Miguel JS,Durie B,et al.International staging system for multiple myeloma.J Clin Oncol,2005,23:3412-3420.
-
7Augustson BM,Begum G,Dunn JA.et al.Early mortality after diagnosis of multiple myeloma:analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party.J Clin Oncol,2005,23:9219-9226.
-
8Ludwig H,Drach J,Graf H,et al.Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.Haematologica,2007,92:1411-1414.
-
9Chanan-Khan AA,Kaufman JL,Mehta J,et al.Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure:a multicenter retrospective study.Blood,2007,109:2604-2606.
-
10Roussou M,Kastritis E,Migkou M,et al.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.Leuk Lymphoma,2008,49:890-895.
同被引文献53
-
1李艳春 孙倩美 徐晨 等.多发性骨髓瘤并发急性肾衰竭临床特点研究[J].中国全科医学,2009,12:1376-1378.
-
2Batuman V.Proximal tubular injury in myeloma.Contrib Nephrol,2007,153:87-104.
-
3Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 2009, 23: 3-9.
-
4Dufie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myelorna. Leukemia, 2006, 20: 1467- 1473.
-
5Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 2003, 13: 176-181.
-
6Greipp PR, Miguel JS, Durie B, et al. International staging system for muhiple myeloma. J Clin Oncol, 2005, 23: 3412-3420.
-
7Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase Ⅱ clinical trial. Leukemia, 2009, 23: 1337-1341.
-
8Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol, 2008, 26: 5775-5782.
-
9Palmnbo A, Bringhen S, Rossi D. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled thai. J Clin Oneol, 2010, 28: 5101-5109.
-
10Kaufman JL, Nooka A, Vrana M, et al. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer, 2010, 116: 3143- 3151.
引证文献5
-
1周建中.多发性骨髓瘤的肾功能改变[J].白血病．淋巴瘤,2010,19(12):751-753. 被引量：1
-
2杨光忠,陈文明,申曼,付丽娜,姜鸾,高文,张蕾,吴垠.BTD、MPT方案序贯治疗新诊断的非移植多发性骨髓瘤患者的疗效分析[J].白血病．淋巴瘤,2011,20(6):350-352. 被引量：1
-
3王岩,黄仲夏,李寒.转化生长因子β在轻链致骨髓瘤肾病上皮间质转化过程中的作用[J].国际移植与血液净化杂志,2013,11(2):19-21.
-
4安娜,李新,申曼,陈世伦,黄仲夏.以肾功能不全起病的多发性骨髓瘤69例临床分析[J].中华内科杂志,2016,55(10):764-768. 被引量：3
-
5魏宇君,李新,申曼,张佳佳,詹晓凯,汤然,黄仲夏.肾意义的单克隆免疫球蛋白血症病例报道并文献复习[J].中国全科医学,2021,24(18):2359-2363. 被引量：3
二级引证文献8
-
1周惠玉,孙伟才,张福军,陈丹,陈微,祝好燕,粱丽,陈涌泉.β2-MG、Cys-C、uNGAL、uMA、uCr、uMA／Cr检测对多发性骨髓瘤早期肾功能损害的诊断价值[J].国际医药卫生导报,2018,24(2):181-184. 被引量：6
-
2陈正,王萍,胡晓梅,何丹珠,丁进亚,黄前川.IgA型多发性骨髓瘤双M蛋白带的鉴定及其临床意义[J].华南国防医学杂志,2018,32(12):842-845.
-
3梁惠如,邹茂权,萧杏贤,李斌,陈荣伴.PCD与VAD化疗方案在MM合并肾衰竭患者中的疗效对比及对患者肾功能的影响[J].中国中西医结合肾病杂志,2020,21(8):714-716. 被引量：2
-
4魏宇君,李新,申曼,张佳佳,詹晓凯,汤然,黄仲夏.肾意义的单克隆免疫球蛋白血症病例报道并文献复习[J].中国全科医学,2021,24(18):2359-2363. 被引量：3
-
5俞玲.多发性骨髓瘤患者肾损伤预测模型的构建[J].广东医学,2021,42(7):802-805. 被引量：6
-
6柴雄兵,韩婷姣,王培华.uKAP、24 h Pro、uLAM在多发性骨髓瘤肾功能不全患者中的表达水平及临床意义[J].检验医学与临床,2022,19(16):2231-2234.
-
7许燕燕,杨翌翔.骨髓增生异常综合征伴意义未明单克隆免疫球蛋白血症1例[J].国际医药卫生导报,2022,28(20):2941-2943.
-
8庄晶,曲悦,姜鸿.单克隆免疫球蛋白血症合并肾损害患者临床病理特征及预后分析[J].临床肾脏病杂志,2023,23(9):705-711.
-
1李春兰.多节段脊柱结核TSRH内固定联合化疗8例护理体会[J].齐鲁护理杂志,2007,13(22):37-38.
-
2李剑,周道斌,焦力,段明辉,韩冰,张薇,赵永强,沈悌.硼替佐米联合地塞米松治疗10例合并肾功能不全的初治多发性骨髓瘤患者疗效分析[J].中华血液学杂志,2009,30(7):487-488. 被引量：5
-
3张冰,陆志华.多发性骨髓瘤并发尿毒症透析患者临床特点分析[J].中国血液净化,2004,3(2):115-116. 被引量：1
-
4龙海深,李秀军.中西医结合治疗急性白血病15例[J].现代养生,2016,0(12):130-130.
-
5黎金庆,唐超生,莫东华,周润华,林栩.多发性骨髓瘤患者肾功能状态与化疗后死亡的关系[J].右江民族医学院学报,1998,20(2):186-188.
-
6武贵存,魏长宏,宋智兴,毛新力,徐从高.硼替佐米、地塞米松、沙利度胺联合治疗多发性骨髓瘤合并肾功能衰竭2例分析[J].山东医药,2009,49(45):100-100.
-
7潘元星,米川,施学东,王冰.经皮椎体成形术治疗多发性骨髓瘤患者椎体多发病理骨折44例临床分析[J].解放军医学杂志,2016,41(11):945-948. 被引量：10
-
8熊丹,李末娟,李庆华,梁亮,吴东红.多发性骨髓瘤患者血清胱抑素C的检测及其临床意义[J].中国实用医药,2016,11(18):10-11. 被引量：2
-
9曹阳,贾怀玉,董骏武.以肾病综合征为首发表现的多发性骨髓瘤患者1例报告[J].中国中西医结合肾病杂志,2007,8(5):298-298. 被引量：3
-
10覃变珍,王智俊.多发性骨髓瘤病理骨折的另发因素与针对性护理[J].临床医药实践,2003,12(11):863-864.
